ESR1 and breast carcinoma: In the previous years, mostly in the nineties and early two thousand, a few investigational attempts of immunotherapy in advanced breast cancer, including the ER+ subtype, were carried out based on the use of cytokines, mainly interleukin-2 or interferons alone or with anti-oestrogens.